Home » Newsletters » BioWorld Science

BioWorld Science

June 8, 2000

View Archived Issues

Study links stress and cortisol levels in infancy to alcohol consumption in adulthood

Neuroprotective substance found in tobacco

Xenon Genetics and Warner-Lambert collaborate on treatments for low HDL cholesterol

Discovery reports positive clinical results for SuperVent in cystic fibrosis

Washington scientists link apoE to a major cause of bleeding strokes

Company Profile: Active Pass

Teva's Copaxone recommended for approval in U.K.

Allegra now available to treat seasonal allergies and chronic hives in children

Provigil authorized for marketing in Italy for the treatment of narcolepsy

New marketing approvals for Gonal-F in both female and male infertility

Chiron and PharmBio Growth Fund form Singapore-based drug discovery venture

Lexicon Genetics discovers gene controlling onset of aging, cancer in mice

Restricted access program for Prepulsid to be implemented in Canada

Down's syndrome research expedited by decoding of human chromosome 21

SafeScience initiates phase II trial for colorectal carcinoma drug candidate

Good safety and evidence of persistent gene transfer obtained in phase I study of tgAAV-CF

AAV-mediated factor IX gene transfer as a therapy for hemophilia B

Available clinical data on tgDCC-E1A summarized; new formulation heads for clinic

Antisense oligonucleotides targeting IGF-I receptor mRNA as new approach to psoriasis

AHP reveals novel series of PTP1B inhibitors for metabolic disorders

Selective EP2-binding agents and their therapeutic use claimed by Ono

New LDL-related protein TANGO-136 isolated and characterized

Roche scientists disclose new series of protein kinase inhibitors and their use

Imidazole-based hypoglycemic/hypolipidemic agents under study at Sumitomo

Scriptgen presents new synthetic compounds that inhibit bacterial enzymes

Recently issued patent covers new GH secretagogues from BMS

New compounds for schizophrenia emerge from R&D at SmithKline Beecham

Hepatitis C virus NS3 helicase inhibitors designed at Vertex

ISIS-2503 under clinical evaluation, alone and in combination, for advanced cancers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...